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Abstract 
Giant cell glioblastoma (gcGB), a subtype of glioblastoma (GB), is characterized by 
presence of numerous multinucleated giant cells. The prognosis for gcGBM is poor; 
however, some reports indicate a better clinical outcome when compared to classic 
GB. So far, the molecular alterations that lead to the multinuclear phenotype of gcGB 
have not been elucidated. Recent reports suggest a role of the mitotic Aurora B 
kinase in the development of multinucleated cells in gcGB. We therefore analyzed 
Aurora B in gcGB and GB, respectively. No mutations in the aurora B gene (AURKB) 
were found, however its mRNA levels and protein levels were significantly higher in 
gcGB than in GB. 59% of gcGB, but only 18% of the matched GB samples showed 
p53 mutations. Ectopic overexpression of Aurora B induced a significant increase in 
the proportion of multinucleated cells in U373-MG (p53 mutant) but not in U87-MG 
(p53 wild-type) cells. In addition, RNAi of p53 in U87-MG led to an increase in the 
fraction of multinucleated cells which was further augmented by ectopic 
overexpression of Aurora B. We suggest that loss of p53 function and deregulated 
Aurora B protein levels might represent essential factors driving the development of 
multinuclear cells in gcGB.   
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Introduction 
Giant cell glioblastoma (gcGB) is a rare variant of glioblastoma characterized by a 
predominance of large, multinucleated giant cells (1). GcGB accounts for less than 
1% of all brain tumors and approximately 5% of all glioblastomas (2;3). Although the 
prognosis is usually poor, some reports suggested that this glioblastoma variant is 
associated with a more favorable prognosis than classic glioblastoma (GB) (3-6). 
The genetic and molecular events leading to the phenotype of gcGB cells have 
remained largely uncertain. Because of the appearance of huge cells displaying 
enormous nuclei or multiple nuclei, defects in late mitosis may be responsible for this 
particular phenotype. It is anticipated that members of mitotic kinases such as polo-
like kinase and Aurora-like kinases are associated with disturbed chromosomal 
segregation and defective or incomplete cytokinesis in cancer cells (7). Indeed, a 
previous report indicated that gcGB specimens and especially the fraction of 
multinucleated giant cells had a non-functional Aurora B kinase (8). Aurora B is a 
serine/threonine kinase belonging to the family of mitotic Aurora kinases which are 
evolutionary conserved from yeast to human (9). Overexpression of Aurora B mRNA 
and protein are frequently detected in human cancer cells (10-12). During the onset 
of mitosis Aurora B kinase is maximally expressed and forms, with its molecular 
partners inner centromeric proteins (INCENP), survivin, and borealin, the 
chromosomal passenger complex (CPP) (for review see (13)). Within the passenger 
complex, Aurora B provides kinase activity toward multiple proteins involved in 
chromosomal segregation and cytokinesis. Aurora B modifies chromatin by 
phosphorylation of centromere protein A (CENP-A) (14) and histone H3 (15) and 
thus contributes to the process of chromatin condensation and kinetochore 
maturation. In addition, Aurora B is involved at the spindle checkpoint and regulates 
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cytokinesis by phosphorylating target proteins in the cleavage furrow such as 
vimentin (16), desmin (17), and MgcRacGAP (18). 
Only within the CPP Aurora B is phosphorylated at Thr-232 by an 
autophosphorylation mechanism, which is indispensable for Aurora-B kinase activity 
(19). Therefore, inactivation of one of the components of the CPP by siRNA or the 
ectopic overexpression of mutant forms of CPP proteins leads to a defective spindle 
checkpoint resulting in disturbed chromosomal segregation and incomplete 
cytokinesis (9;20-23). 
GcGB have a higher frequency of p53 mutations and have a lower frequency of 
EGFR amplifications than GB (3;5;24;25). P53 is a key player in the regulation of the 
cell cycle and induction of apoptosis, by transcriptional activation of inhibitors of 
cyclin dependent kinases, such as p21waf/cip and by transcriptional activation of pro-
apoptotic genes such as PUMA, Bax or Bad (26-28). However, in the setting of 
gcGB, p53 deficiency may allow that Aurora B dysfunction induces the development 
of multinucleated giant cells. In addition, a recent report revealed that the small 
chemical compound VX680, which blocks Aurora kinases, led to a significant 
increased endoreplication in p53-deficient cells when compared to cells having intact 
p53 function (29). We hypothesized that cells with aberrant Aurora B function, due to 
the loss of functional p53, likely cannot arrest the cell cycle and repetitively undergo 
multiple rounds of genome replication without completion of cytokinesis.  
In the current study, we investigated whether the appearance of multinucleated cells 
in gcGB is caused by mutations in the Aurora B gene or associated with altered 
Aurora B expression levels, and concomitant mutations in the tumor suppressor 
protein p53. We here provide evidence that the phenotype of gcGB is linked to a 
higher expression of functional Aurora B and loss of p53 function. To reveal a 
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connection between Aurora B expression and p53 loss of function, we transduced 
human glioma cells (p53 wild-type (wt), p53-mutant, and cells depleted for p53 by 
RNAi) with retroviral vectors encoding for Aurora B and found that loss of p53 
function and concomitant overexpression of Aurora B significantly increased the 
fraction of multinucleated giant cells.  
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Material and Methods 
Tissue samples 
28 gcGB cases and 54 age and gender matched GB cases were provided by the 
German Glioma Network and associated centers and were evaluated by 
immunohistochemistry in this study. From these samples 17 gcGB and 22 classic 
GB samples were additionally analyzed at the DNA and mRNA levels (i.e. genomic 
analysis, quantitative mRNA analysis). Tissues were obtained in the course of 
surgery or diagnostic biopsies with informed consent and approval by the local ethics 
committees. Whole tissue sections of 14 cases of gcGB and tissue arrays of further 
14 cases with 1-5 cores per case with a diameter of 1.5 mm from representative 
areas were compared with tissue arrays of 33 classic GB cases and whole tissue 
sections of 21 GB. In addition, tissue arrays of 47 cases of other gliomas of varying 
dignity were tested. These arrays included 22 cases of anaplastic gliomas WHO 
grade III, and 25 cases of low grade gliomas WHO grades I and II. Furthermore, 3 
specimens of normal brain tissue from patients with epilepsy served as controls in 
the quantitative PCR analysis of transcripts and immunohistochemistry: For 
immunohistochemistry, additional 10 tissues from non-neoplastic areas of patients 
with gliomas of varying malignancy were used as controls. 
 
Cell lines 
U373–MG is a glioblastoma/astrocytoma-derived cell line, U87-MG, is a 
glioblastoma-derived cell line. U87-MG contains wild-type p53, (30) the U373 cell 
line expresses mutant p53 (31). The cells were cultured in Basal Minimal Eagle 
medium (BME, Invitrogen, Karlsruhe, Germany) supplemented with 2 mM L-
glutamine and 1% non-essential amino acids (Biochrom, Berlin, Germany). 293T are 
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human embryonic kidney cells. They were cultured in Dulbecco´s modified Eagle 
medium containing 4.5 g/l glucose (PAA Laboratories, Pasching, Austria). The 
medium was supplemented with 10% heat inactivated fetal calf serum, 100 U/ml 
penicillin and 100 µg/ml streptomycin (Invitrogen). 
 
Analysis of genomic p53 and Aurora B mutations 
Mutational analysis of the coding regions of p53 known to contain the DNA-binding 
domain and the hot spot mutation sites (32) (exons 5-9; for primer sequences see 
supplementary material) was performed after amplification of exons 5, 6, 7 and 8/9 
using (synthesized by Eurofins MWG Operon, Ebersberg, Germany) an amplification 
protocol described elsewhere (33). In addition, exons 2-9 of Aurora B, representing 
the ATP-binding domain and the kinase domain were analyzed using the primers 
AURKB_Ex2for 5´-GGAAACAGCTATGACCATGCTCGGGCTAGCGCT TCCGGC-
3´, AURKB_Ex2rev 5´TGTAAAACGACGGCCAGTGCAGGAACTCGCCA 
TGCGGGGTC-3´, AURKB_ Ex3/4for 5´-GGAAACAGCTATGACCATGGGCACCC T 
CAGAGCTACCCCCTG-3´, AURKB_Ex3/4rev 5´-TGTAAAACGACGGCCAGTCG 
TCCACCCCCAGGCTTGGGGCA-3´, AURKB_Ex5for 5´-GGAAACAGCTATGACCA 
TGGGATGAGGAAGCAGAGAGAAAGCAAACCTCT-3´, AURKB_Ex5rev 5´-TGTAA 
AACGACGGCCAGTAGGGGCTTCGGCTCAGGGGGCATC-3´, AURKB_Ex6/7for 
5´-GGAAACAGCTATGACCATGCTGGGCCACGTCTGACCCCAGTTTGC-3´, AURK 
B_Ex6/7rev 5´-TGTAAAACGACGGCCAGTCTCACACCCAGGTCTGGCCTCCC 
AGG-3´,AURKB _Ex8for 5´-GGAAACAGCTATGACCATGGCCGTCAGGCAGCAG 
GGAAAG-3´, AURKB_Ex8rev 5´- TGTAAAACGACGGCCAGTCTGGCTTCAGCAG 
CTGGCACG-3´, AURKB _Ex 9 for 5´-GGAAACAGCTATGACCATGCCAGGGTGAA 
ACTAATGCAGCCCTTCC-3´, and AURKB_Ex9rev 5´-TGTAAAACGACGGCCAGT 
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GCTTCCTCCACAGCAAAGCCTCCAC-3´ (all synthesized by Eurofins MWG 
Operon). The bands representing the amplicons were excised from the agarose gels 
and eluted by the use of the QiaQuick gel extraction kit (Qiagen, Hilden, Germany). 
Subsequently, the DNA was sequenced (Sequencing Facility, MPI-CBG, Dresden, 
Germany) and analyzed.  
 
mRNA preparation, cDNA synthesis and quantitative PCR 
Total mRNA of tumor samples was prepared with the RNAeasy kit from Qiagen 
(Hilden, Germany) according to the instructions of the provider. cDNA was generated 
using 1 µg total mRNA, Oligo (dT)12-15 primer (GE Healthcare, Freiburg, Germany)  
and the Omniscript reverse transcriptase kit (Qiagen). Based on the LightCycler (LC) 
technology (Roche, Mannheim, Germany), quantitative real-time PCR (QPCR) 
assays were established in order to quantify the mRNA expression of survivin, 
aurora B and of the housekeeping gene β-actin. The levels of a specific PCR product 
were determined by the use of TaqMan probes (β-actin-TM: 5´-6FAM-
CAgCTTCACCACCACggCCAXT-PH; Survivin-TM: 5´-6FAM-CCACTgCCCCACT 
gAgAACgAgCXT-PH; Aurora B-TM 5´-6FAM-TgTgCATgCgCCCTCCCTgAgTXT-PH) 
(all synthesized by TIB MOLBIOL Syntheselabor GmbH, Berlin, Germany). As PCR 
primers we used LC-BETA_ACTIN_FOR 5´-tcaccgagcgcggct-3´, 
LC_BETA_ACTIN_REV 5´-taatgtcacgcatttccc-3, LC_SURVIVIN_FOR 5´-gccgaggct 
ggcttca-3´, LC_SURVIVIN-REV 5´-gaagaaacactgggccaagtct-3´, and LC-
AURORA_B_FOR 5´-gattgctgacttcggctggt-3´, LC-AURORA_B_REV 5´-ggtgccacaca 
ttgtcttctt-3´ (all synthesized by Eurofins MWG Operon) . The levels of all transcripts 
were determined by an amplification protocol consisting of a denaturation step at 95 
°C for 10 min, followed by 40 cycles with a 95 °C denaturation step for 15 s, 61 °C 
 9 
annealing  for 5 s and a 72 °C extension step of 5 s. Standard curves were 
generated applying dilutions over six log scales (101–106) per capillary using a 
pEGFP-Actin vector (Takara-Clontech, Heidelberg, Germany) and plasmids 
encoding aurora B and survivin, respectively, and were used to calculate the 
amplification products. All measurements were performed with aliquots from the 
same cDNA batches to guarantee standardized and comparable conditions. A 
negative control (no template) was included in each of the PCR runs. The cDNA 
copy numbers of aurora B and survivin mRNAs were normalized to the quantitative 
measurements of β-actin mRNA levels. All PCR runs were repeated twice or 
threefold to ensure reproducibility and reliability and were determined by the Light 
Cycler quantification software version 3.5 (Roche).  
 
Histology and immunohistochemistry 
Five µm thick serial sections from paraffin-embedded tissues and tissue arrays were 
cut and processed for staining with hematoxylin-eosin (H&E), and for 
immunohistochemistry, which was performed using the indirect avidin-biotin-
peroxidase complex method (LSAB II, Dako, Glostrup, Denmark). Monoclonal rabbit 
anti-Aurora B (clone EP1009Y, Epitomics/Biomol, Hamburg, Germany), and 
polyclonal anti-phospho-232T Aurora B (BIOTREND, Cologne, Germany), anti-Ki67 
(monoclonal MIB-1, Dako) and monoclonal anti-p53 (Calbiochem, Bad Soden, 
Germany), were applied at a concentration of 10 µg/ml for 1 h with pre-treatment by 
microwave heating for 2 x 5 min, in 10 mM sodium citrate, pH 6.2. Biotinylated pre-
adsorbed secondary antibodies were provided with the LSAB II-kit. 
Diaminobenzidine (DAKO) (10 µg/ml in 0.02% hydrogen peroxide/PBS) was used as 
chromogen. Counterstaining was performed with hematoxylin (7 g/l; Merck, 
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Darmstadt, Germany). For blocking of nonspecific binding sites, nonfat dry milk (5%) 
in PBS was used. To block the endogenous peroxidase, the sections were immersed 
for 10 min in PBS containing 1% hydrogen peroxide.  Immunoreactions (IR) of 
Aurora B were evaluated as counted percentages of stained chromosomes and 
positive nuclei, restricted to one nucleus per cell. For p53, the comparison with the 
proliferation marker Ki67 was used for the analysis. P53 wild-type protein often can 
be detected in the nuclei of proliferating Ki67-positive tumor cells. In contrast p53 
mutant forms also accumulate in the nucleus of Ki67-negative cells which are not in 
active phases of the cell cycle. P53 was distributed to three different groups as 
follows: The cases were regarded as negative for mutant p53 when nuclear staining 
occurred not at all or only in proliferating cells, Moderate expression was assumed 
when p53 showed more than a twofold increase over the proliferation measured by 
Ki67 positive cells, but less than 50% of all cells, Above these numbers, strong 
expression was noted. For statistical evaluation Student´s- t-test and the chi-square 
test were used. 
 
Transduction of retroviral vectors 
The retroviral vector pcz-CFG5.1-EGFP encoding EGFP has been described 
previously (34). A retroviral vector encoding a functional EGFP-Aurora B fusion 
protein was constructed by introducing a BamHI / BglII-fragment encoding the full 
coding sequence of Aurora B into the BamHI-site of the vector pcz-CFG2-fEGFPf 
(22). For the transduction of DNA-sequences encoding shRNA-molecules we used 
the self inactivating retroviral Moloney murine leukemia virus backbone pRVH-1-
puro. This vector contains a H1 polymerase III promoter for the expression of shRNA 
molecules in reverse orientation. We utilized the sh53 small hairpin RNA sequence 
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described previously (35). The upper DNA strand: (5‘-gatccccgactccagtggtaatctact 
tcaagagagtagattaccactggagtctttttggc-3´) and bottom DNA strand (5´-tcgagccaaaaag 
actccagtggtaatctactctcttgaagtagattaccactggagtcggg-3´) were synthesized by 
(Eurofins MWG Biotech) annealed and ligated into the BglII / SalI-restrictions sites of 
pRVH-N1-puro generating pRVH-1-shP53-puro and pRVH-1-shLuc-puro. As control 
we included a small hairpin RNA targeting luciferase (36). Retroviral particles were 
generated as described previously (22). Briefly, 293T cells were cotransfected with 
an expression construct for gag-pol (pHIT60) (37), the MoMuLV-based retroviral 
vectors and the vesicular stomatitis virus G-protein (pMD.G2, kindly provided by D. 
Trono, University of Geneva, Switzerland). Viral supernatants were harvested 48 and 
72 h after transfection. 105 target cells were plated in 30 mm dishes a day before 
transduction and were transduced with retroviral supernatants at a multiplicity of 
infection (MOI) of 20. Cells transduced with pRVh-1-shLuc-puro and pRVh-1-shp53-
puro were selected for 48h using cell culture medium containing 10µg/ml puromycin 
(Takara Clontech). 
 
Western Blot analysis 
Cells grown in 6 well-plates were harvested in 120 µl 2x Laemmli-protein-sample-
buffer (Sigma, Taufkirchen, Germany). Samples were subsequently cooked for 5 min 
and placed in an ultrasonic bath for 15 min. Equal amounts of protein lysates were 
separated in 10% polyacrylamide gels. The Proteins were blotted semidry from the 
gels onto PVDF membranes, which were subsequently blocked over night in TBS 
buffer + 5% milk powder. Then membranes were washed 3 times for 10 min in TBS 
+ 2% Triton X-100, 0.5% Tween 20 and another 10 min in TBS. The membranes 
were incubated with anti-Aurora B (rabbit polyclonal; 1:1000; Sigma), anti p53 (goat 
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polyclonal; 1:1000; R&D Systems, Wiesbaden, Germany) or anti α-tubulin (mouse 
monoclonal; 1:5000; Sigma). After incubation with the primary antibody the 
membranes were washed 3 x with TBS-TT and 1 x 10min with TBS-buffer. 
Subsequently the membranes were incubated for 1 hour with appropriate species 
specific secondary antibodies conjugated to HRP (1:1000; Dako, Glostrup, 
Denmark). The membranes were washed again and imaged with ECL-detection 
solution (GE Healthcare, Freiburg, Germany) in a LAS3000 device.  
 
Investigating multinuclear cells and DNA analysis 
Analysis of polyploidy was determined by flow cytometry using propidium iodide-
stained cells. Briefly, the cells were washed in PBS and fixed in 70% (v/v) ethanol. 
After centrifugation of the cell at 600 g at 20°C for 10 min, the pellet was suspended 
in 0.5 ml DNA extraction buffer (4 mM citric acid in 0.2 M Na2HPO4; pH 7.8). After 5 
min incubation at room temperature the cells were spun down at 600 g. The cells 
were then washed once with PBS, followed by incubation in PBS containing 40 µg/ml 
propidium iodide (Sigma) and 200 µg/ml RNase A (Sigma) for 1 h at room 
temperature in the dark. Stained nuclei were then analyzed using a Becton Dickinson 
FACScan using cell quest software (BD, Heidelberg, Germany) with at least 10,000 
events / determination. Statistical analysis was performed with Student´s t-test. 
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Results 
p53 and Aurora B mutational status and differential expression of Aurora B 
mRNA in giant cell glioblastomas and classic glioblastoma 
The exons 2-9 of the Aurora B gene of giant cell glioblastoma and classic GB were 
screened for mutations however, no mutations were found (data not shown). In 
contrast, p53 mutations were frequent in giant cell glioblastoma (59%) whereas only 
18% of the classic GB samples carried p53 mutations (table 1).  
The relative quantification of the mRNA expression levels of Aurora B in gcGB 
samples and GB samples was accomplished by quantitative PCR. In each sample 
high copy numbers for β-actin mRNA were found, confirming the quality of the 
mRNA preparations and reverse transcription reactions. Furthermore, we included 
QRT-PCR analysis of Aurora B’s molecular partner Survivin in our studies. 
Concomitant expression of mRNA encoding Survivin and Aurora B proteins was 
found in 12 of 17 giant cell glioblastoma samples and 15 of 21 GB samples. No 
Survivin and Aurora B transcripts were found in normal brain controls (data not 
shown).   
No significant difference was found in the levels of Survivin mRNA expression in 
gcGB when compared to GB. However, we noted a significant 5-fold increase in 
Aurora B mRNA copy numbers in gcGB relative to GB (see Fig. 1). 
 
Increased expression of Aurora B protein in giant cell glioblastoma 
In order to get an overview of Aurora B expression and its subcellular localization in 
normal and malignant brain tissues and to verify the results obtained by the 
quantitative PCR analysis, normal brain and different brain tumors were investigated 
by immunohistochemistry. Immunoreactivity for Aurora B was absent in normal 
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controls (data not shown). In all brain tumor samples investigated, Aurora B signals 
were detected and were mostly restricted to the cell nucleus. However, Aurora B 
signals were barely present in low grade gliomas WHO grades I-II, with a mean 
value of 0.53 % positive cells (Fig. 2A, G). Anaplastic gliomas of WHO grade III 
showed higher numbers of nuclear staining (mean 1.74 %) and slight cytoplasmic 
staining in some cases (Fig. 2B, G). A significant increase (p<0.01) in Aurora B 
signals was observed in classic GB WHO IV (mean 4.71%) when compared to 
gliomas of WHO grades I-III (Fig. 2C, G). However, there was a further significant 
increase of Aurora B immunoreactivity in gcGB (mean 11.98%, p< 0.001) when 
compared to classic GB (Fig. 2D-F, G). Here, two distinct populations were 
observed: one population of frequently multinucleated giant cells with high nuclear 
levels of Aurora B and some cytoplasmic staining (Fig. 2E) and a second population 
of smaller cells resembling tumor cells in classic GB (Fig. 2F). Quantitative analysis 
of the fraction of cells with nuclei positive for Aurora B staining of gliomas of varying 
malignancy revealed that an increase of nuclear Aurora B expression correlated with 
the WHO grade. However, gcGB samples displayed significantly more Aurora B 
positive nuclei and also more cytoplasmic Aurora B-staining than all other gliomas of 
grades WHO grades I-IV (Fig. 2G). 
Some gcGB cells were detected that displayed condensed chromosomes heavily 
stained for Aurora B (see Fig. 2E) suggesting a correct function of Aurora B in the 
early phases of mitosis. This notion was supported when phospho-232T Aurora B 
was detected in the nuclei of both, giant cell glioblastoma (3A, B) and classic GB 
(Fig. 3C, D).  
The immunohistochemical assessment of p53 expression revealed a moderate to 
strong nuclear staining in 28 % of classic GB and in 75 % of gcGB, thus showing a 
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significant difference between these groups (p< 0.001), which is in line with the 
results obtained by the p53 mutational analysis. In gcGB, nuclear p53-IR appeared 
more frequently in giant cells and in the population of cells with large pleomorphic 
nuclei as compared to the cells with small more regularly shaped nuclei (Fig. 3 E, F).  
  
P53-deficient glioma cells develop a giant cell GB-like phenotype upon ectopic 
expression of Aurora B  
In order to functionally elucidate the p53-Aurora B connection, we transduced glioma 
cell lines with retroviral vectors encoding EGFP-Aurora B or EGFP, respectively. We 
used the EGFP-Aurora B fusion gene because it allowed the measurement of 
transduction efficiencies, could be used to immediately identify the subcellular 
localization during mitosis, and enhanced the analysis of polyploidy. The 
transduction efficiencies of U87-MG and U373-MG cells routinely were in the range 
of 85% to 99% (Fig. 4A). Transduced EGFP-Aurora B was mostly nuclear in 
interphase and was localized the kinetochors in metaphase, at the cleavage furrow 
in anaphase (see Fig. 4C) and in the midbody in late telophase. Five days after 
transduction of Aurora B, the p53-deficient U373-MG glioma cells increased in size 
and acquired multiple nuclei (Fig. 4B, D). However, some U373 giant cells displayed 
multiple cleavage furrows (see Fig. 4C) and multiple midbodies (data not shown) 
suggesting that they were able to occasionally resolve polyploidy by creating multiple 
daughter cells (Fig. 4C). In contrast U87-MG cells containing wild-type p53 showed 
neither an altered morphology nor an increase in the number of nuclei (Fig. 4D). As 
controls we included transductions of a retroviral vector encoding EGFP in U373-MG 
and U87-MG. As expected, no effects of EGFP expression on cell morphology and 
polyploidy were monitored in both glioma cell lines.  
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Similar results were obtained when the genomic DNA content of transduced cells 
were analyzed by propidium iodide staining and cytometry. Here, the p53-deficient 
U373-MG cells transduced with EGFP-Aurora B showed a gradual increase in the 
fraction of cells containing 4N and 8N genomes at 48 h after transduction and a 
striking increase of cells containing 4N and 8N genomes at 72 h (Fig. 5A, C). 
However, only a moderate but significant increase in polyploidy was noted 72 h after 
transduction of EGFP-Aurora B in U87-MG glioma cells containing wild type p53 
(Fig. 5B, C). Yet, the transduction of the control vector encoding EGFP had no effect 
on the cell cycle and the genomic DNA content. Interestingly, overexpression of 
EGFP-Aurora B led to a significant increase in the fraction of apoptotic cells in both 
cell lines when compared to the control cells expressing only EGFP (Fig. 5 A, B).  
To further verify the impact of p53 loss of function and Aurora B overexpression on 
glioma cells we generated U87-MG with stable expression of a provirus encoding a 
small hairpin RNA targeting p53. As control we included cells transduced with a 
control vector encoding a small hairpin RNA targeting luciferase (Fig. 6A). The 
silencing of p53 led to a significant increase in the fraction of cells bearing a DNA 
content >4N, when compared to shLuc transduced control cells. A subsequent 
transduction of EGFP-Aurora B further significantly augmented the development of 
multinucleated cells in p53-depleted cells whereas no such effect was observed in 
control cells expressing p53 wild type protein (Fig. 6B). 
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Discussion 
The mitotic Aurora B kinase has been reported as being highly expressed in various 
types of transformed cells (10-12). In glioblastoma an increase in Aurora B 
expression has been associated with a shorter survival (38). Our 
immunohistochemical analysis of Aurora B in various grades of astrocytic glioma 
also revealed that the level of expression increased with malignancy. However, 
strongest expression of Aurora B was noted in gcGB, which recently has been 
reported to be associated with a better clinical outcome when compared to patients 
suffering from classic GB (39). It has been reported that GcGB has a less infiltrative 
growth pattern than classic GB (40;41). Thus depending on the individual case gcGB 
often has been described intraoperatively as having a confined demarcation and 
firmness which makes a gross-total resection of the tumor more amendable which is 
relevant for the outcome (3;42). Another report indicated a dysfunction of Aurora B 
kinase in the early mitotic phase and in cytokinesis in giant cell glioblastoma (8) 
which should lead to decreased proliferation, and therefore might give an 
explanation on the molecular level for the better prognosis in gcGB patients. Fujita et 
al. investigated the site-specific phosphorylation of Aurora B substrates in gcGB 
specimens, in particular histon H3 (Ser28) phosphorylated in prophase (15), and 
vimentin (Ser72) phosphorylated in cytokinesis (16). Although gcGB cells expressed 
Aurora B and enter early mitosis, P-Ser-28-histon H3 and P-Ser72-vimentin 
immmunosignals were not detected in giant cell glioblastoma cells. Therefore, the 
authors suggested that Aurora B kinase function was absent in gcGB. However, the 
mechanism leading to the inactivation of Aurora B function, i.e. caused by mutations 
in the ATP-binding domain or of the kinase domain, was not investigated. To 
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address this point, we directly sequenced exons 2-9 of the Aurora B gene in 17 giant 
cell glioblastoma samples. However, no mutations were detected.  
The majority of the gcGB samples had mutations in the p53 gene. This observation 
and the immunohistological analysis of p53 staining are in line with previous studies 
showing a higher incidence of p53 mutations in gcGB when compared to other 
primary glioblastomas (3;5).  
Next, we found that gcGB expressed significantly more Aurora B kinase mRNA and 
protein than classic GB. In contrast, no significant differences in mRNA expression 
levels of Survivin were noted. The immunohistochemical analyses revealed that 
more nuclei contained Aurora B immunosignals in gcGB samples when compared to 
classic GB. Furthermore, the Aurora B immunosignals were most prominent in the 
nuclei of the multinucleated giant cells. An additional Aurora B staining was noted in 
the cytosol. Giant cells bearing heavily condensed chromosomes and strong Aurora 
B immunosignals were frequently observed, which confirms that the gcGB cells were 
able to enter prometaphase. Furthermore, phospho-232T Aurora B kinase was 
detected in nuclei of giant cell glioblastoma cells, indicative of activated Aurora B. 
These observations contrast the recent report from Fujiita et al. (8). These authors 
reported an early mitotic arrest of multinuclear U251-MG cells, which was 
accompanied by lack of Aurora B-mediated histon H3 phosphorylation and 
chromosome condensation, respectively. We cannot explain these differences; 
however, we assume that caution is advised when comparing the phenotypes of 
permanent glioma cell lines and giant cell glioblastoma in vivo. We assume that both 
overexpression and down-modulation of Aurora B activity may lead to similar 
phenotypes and that a fine regulation during the cell cycle is necessary for normal 
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Aurora B function. In fact, a recent report demonstrates that silencing of Aurora B in 
p53-deficient cells induces polyploidy (21).  
The observation that the protein levels of Aurora B were significantly increased in 
cells of gcGB when compared to classic GB raises the question of how a 
deregulated intracellular Aurora B concentration leads to a multinuclear phenotype. 
We hypothesized that this is likely due to a disturbed stoichometry of the CPP 
proteins during mitosis. Recent studies revealed an increase in the fraction of 
polyploid cells with lack of p53 function after forced expression of Aurora B and 
Survivin, respectively (43-45). To test this hypothesis, we transduced p53-mutant 
and glioma cells containing wild-type p53 with retroviral vectors encoding EGFP-
Aurora B and analyzed the resulting phenotype. Strikingly, an overexpression of 
EGFP-Aurora B in p53-mutant U373-MG caused a time-dependent gradual increase 
in the fraction of multinuclear cells or cells showing a huge nucleus which resembles 
the phenotype found in gcGB. Although nearly all U373 glioma cells were transduced 
with EGFP-Aurora B we only detected 40% of cells displaying giant or multiple nuclei 
5 days after transduction. On the other hand we detected cells showing multiple 
cleavage furrows in anaphase (see Fig. 4C) and midbodies in telophase suggesting 
that cells sometimes were able to segregate polyploid genomes and formed 
daughter cells. However, we were unable to continue the cultivation of giant U373 
cells for a longer time period, because the cells continuously detached and were lost. 
In contrast to U373 cells, U87-MG glioma cells expressing wild-type p53 and 
transduced with EGFP-Aurora B were unaffected. The latter result proved that a 
fusion protein consisting of Aurora B and EGFP had no dominant negative effect on 
mitosis, which is in line with previous reports (46-48). To recapitulate the results by 
using cells with the same isogenic background U87-MG cells either treated with 
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shRNAs targeting p53 or targeting shLuc were analyzed. We found that depletion of 
p53 alone in this cell line enhanced the development of multinuclear cells which was 
further accelerated by ectopic expression of Aurora B. We suggest that the 
development of the multinuclear phenotype of gcGBM may be facilitated by loss of 
function of the tumor suppressor gene p53 and dysregulated Aurora B expression 
leading to an increased endomitosis of the cells. These alterations may contribute to 
the phenotype and biology of this rare variant of glioblastoma. 
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Figure legends: 
 
Table 1: p53 mutational status of 17 gcGB samples and 22 GB samples; n, no 
mutation detected.  
 
Fig. 1: Increased Aurora B mRNA levels in giant cell glioblastoma: QRT-PCR 
analysis of Survivin and Aurora B transcripts in tissue samples of gcGB and classic 
GB. Copy numbers of Survivin and Aurora B transcripts were normalized to β-actin 
mRNA copy numbers. In total 17 gcGB samples and 22 sex and age matched GB 
controls were analyzed. Note that the Aurora B expression was significantly higher in 
gcGB. Survivin mRNA levels were also high in gcGB, however, the difference was 
not significant. *p>0.05 when using Student´s t-test. 
 
Fig. 2: Aurora B immunohistochemistry (IR) in gliomas of different WHO 
grades: A:  Diffuse astrocytoma WHO grade II without noticeable staining for Aurora 
B.  B: Anaplastic oligoastrocytoma WHO grade III with few positive nuclei (see 
arrowheads) and some cytoplasmic background C: Classic GB with an increased 
ratio of nuclei positive for Aurora B (see arrowheads). Note the presence of 
glomeruloid vascular proliferations (see asterisk). D: gcGB with strong nuclear 
staining for Aurora B (see arrowheads). Note an additional moderate increase in 
cytoplasmatic Aurora B staining. E: gcGB cell with a strong nuclear staining of 
Aurora B (see arrowhead). Note the mitotic giant cell displaying chromosomes 
stained for Aurora B (see asterisk)).  F: Small cells in gcGB with moderate Aurora B 
staining. Stained nuclei are depicted (arrowheads). Magnification bars for A-D: 
100µm; for E and F: 50µm. All sections were counterstained with hematoxylin. G: 
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Quantitative analysis of Aurora B expression in gliomas of different WHO grades. 
gcGB were compared to GB WHO grade IV *p<0.001 when using Student´s t-test. 
 
Fig. 3: Expression of phospho-232T Aurora and p53 status in GB and gcGB 
samples. A: Phosphorylated Aurora B is detected in large and smaller tumor cell 
nuclei in a gcGB sample (see arrowheads). B: Phospho-232T Aurora B is also 
detected in small nuclei of a gcGB sample (see arrowheads). C: GB with a high 
percentage of small nuclei positive for phosphorylated Aurora B. D: GB with a low 
percentage of small tumor cell nuclei positive for phospho-232T Aurora B. E: gcGB 
showing strong nuclear staining for p53 mostly in giant cells (see arrowhead) and 
nuclei with marked pleomorphy. F: Immunoreactivity for p53 in a classic GB being 
restricted to only few positive nuclei (arrowheads). All sections were counterstained 
with hematoxylin. Magnification bars for A, B, E, and F: 50µm; for C and D: 100µm. 
 
Fig. 4: Ectopic overexpression of Aurora B causes a gcGB-like phenotype in 
glioma cell with mutant p53: A: To investigate the effect of increased Aurora B 
levels in p53 mutant U373-MG and p53 wild-type U87-MG cells retroviral particles 
encoding EGFP-Aurora B or EGFP were transduced in the glioma cells. 
Representative fluorescent cytometry analyses of transgene expression (EGFP 
fluorescence emission) are shown. B: The U373-MG cells transduced with EGFP-
Aurora B gradually developed huge multinuclear cells (see arrowheads). a, b: 
Representative pictures show U373-MG cells 5 days after transduction with EGFP-
Aurora and c, d: U373-MG cells 5 days after transduction with EGFP control vector. 
Bar represent 30µm. C: a, b: U373 transduced with EGFP-Aurora B showing a 
normal anaphase. a: EGFP-Aurora B signals accumulates at the cleavage furrow 
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(arrow). c, d: Multinuclear U373 expressing EGFP-Aurora B showing an atypical 
anaphase.  a: EGFP-Aurora B accumulates at multiple cleavage furrows (arrows). b, 
d: DNA was counterstained with Hoechst33342 and image was merged with the 
EGFP-images. Bar represents 20 µm D: Quantitative analysis of the fraction of cells 
displaying a huge cell body and multiple or enlarged nuclei. Note that the ectopic 
EGFP-Aurora B expression in p53 mutant U373-MG caused a significant increase of 
giant cells containing multiple nuclei or huge nuclei, whereas no effect was observed 
in p53-positive U87-MG cells. The ectopic expression of EGFP had no effect on the 
appearance of the cells. Bar represents 30 µm. *p<0.05 when using Student´s t-test.  
 
Fig. 5: DNA analysis reveals polyploidy in p53-mutant U373MG cells 
transduced with EGFP-Aurora B: Cell cycle analysis and analysis of apoptotic 
cells by flow cytometry of propidium iodide- stained cells 48h and 72h after 
transduction. The percentage of apoptotic cells is shown in marker M1. The fraction 
of cells with a DNA content of 4N or higher (M2), and of a DNA content of higher 
than 8N (M3) are depicted. A: U373MG cells were transduced with EGFP-Aurora B 
or EGFP control vector. Note the gradual increase in polyploidy and the increase in 
the fraction of cells with fragmented DNA (apoptotic cells) after transduction of 
EGFP-Aurora B. The U373-MG cells transduced with EGFP alone developed no cell 
cycle abnormalities or polyploidy. B: U87-MG cells were transduced with vectors 
encoding EGFP-Aurora B or EGFP. In contrast to the p53-mutant U373-MG cells, 
these cells barely show signs of polyploidy. However, the ectopic expression of 
EGFP-Aurora B led to an increase in the fraction of apoptotic cells. C: Quantitative 
analysis of the fraction of cells accumulating genomic DNA >4N 72h after 
transduction. Note an 8-fold increase in U373-MG cells with polyploidy. In contrast, 
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U87-MG cells containing wild-type p53 show only a moderate increase in the amount 
of cells with DNA content higher than 4N. *p<0.05; **p<0.01 when using Student´s T-
Test. 
 
Fig. 6: Increase in the fraction of multinuclear U87-MG cells after RNAi of p53 
and subsequent transduction of EGFP-Aurora B: A: Western Blot analysis 
showing the steady state expression levels of p53 and of EGFP-Aurora B in cells 
either treated with a shRNA targeting p53 or a treated with a control shRNA (shLuc). 
After puromycin selection the cells were subsequently transduced with retroviral 
vectors encoding EGFP-Aurora B or EGFP. B: Analysis of cells with a DNA content 
>4N reveals induction of polyploidy in p53-depleted cells which is significantly 
increased by transducing a vector encoding EGFP-Aurora B.   
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p53 status in gcGB and GB samples 
       Age  TP53 
Patient Diagnosis Gender (years) exon Codon Mutation 
GB7 gcGB female       54 Exon 8 g.839G>C p.R280T 
 
GB10 gcGB male 71 Exon 5 g.393delC p.N131fs 
 
GB17 gcGB male 36 Exon 8 g.916C>T p.R306X 
 
GB38 gcGB female 11 n 
 
GB141 gcGB male 74 n  
 
GB233 gcGB female 68 Exon 7 g.701A>G p.Y234C 
 
GB236 gcGB female 59 Exon 5 g.487T>G  p.Y163D 
 
GB250 gcGB female 62 Exon 5 g.524G>A p.R175H  
 
GB255 gcGB female 62 Exon 7 g.C749>T p.P250 
 
HT13149 gcGB male 40 n 
 
HT13152 gcGB female 46 n 
 
HT13357 gcGB female 65 n 
 
HT13372 gcGB male 41 n 
 
3089N gcGB male 70 Exon 6 g.638G>A p.R213Q 
 
M3179T gcGB male 70 Exon 5 g.393delC p.N131fs  
 
M3367E gcGB female  59 Exon 6 g.T659>G p.Y220C 
 
M4711E gcGB male 75 n 
 
M3079K GB male 42 Exon 5 g.524G>A p.R175H 
    Exon 8 g.G841>A p.D281N  
 
M2059F GB male 76 n 
 
M2085H GB male 36 Exon 5 g.T400>G p.F134V 
 
M2028F GB male 47 n 
 
M2018A GB female 68 n 
 
M2267C GB female 40 n 
 
M2261A GB male 46 n 
 
M2249T GB male 37 n 
 
M3022P GB male 74 n 
 
M3027N GB male 65 n 
 
M3051K GB male 60 Exon 5 g.A397>G p.M133G 
    Exon 5 g.T403>G p.C135G  
 
M3062T GB female 44 Exon 5 g.G473>A p.R158P 
 
M3081F GB female 74 n  
 
M3096K GB female 72 n 
 
M3100H GB male 75 n 
 
M3197C GB male 45 n 
 
M3112A GB female 62 n 
 
M3140K GB female 70 Exon 6 g.A641>G p.T214T 
 
M3155M GB female 63 n 
 
M4223L GB male 45 n 
 
M4182L GB male 64 n 
 
M2304H GB female 70 n   
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